ORBi: Detailled Reference

Article (Scientific journals)

Tofacitinib De-escalation Strategy in Ulcerative Colitis: Is It the End of the Story?

Guillo, Lucas; Peyrin-Biroulet, Laurent; Louis, Edouard

2021 • In Journal of Crohn's & colitis, 15 (7), p. 1087-1088

Peer reviewed

Permalink
https://hdl.handle.net/2268/266117

DOI
10.1093/ecco-jcc/jjab006

PubMed
33619541

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Tofacitinib De escalation Strategy in Ulcerative Colitis Is It the End of the Story_JCC_PPE.pdf

Publisher postprint (824.47 kB)

© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Colitis, Ulcerative/drug therapy; Humans; Piperidines/therapeutic use; Pyrimidines; Pyrroles

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Guillo, Lucas

Peyrin-Biroulet, Laurent

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

Language :

English

Title :

Tofacitinib De-escalation Strategy in Ulcerative Colitis: Is It the End of the Story?

Publication date :

2021

Journal title :

Journal of Crohn's & colitis

ISSN :

1873-9946

eISSN :

1876-4479

Volume :

15

Issue :

7

Pages :

1087-1088

Peer reviewed :

Peer reviewed

Additional URL :

https://doi.org/10.1093/ecco-jcc/jjab006

Commentary :

© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

Available on ORBi :

since 15 December 2021

Statistics

Number of views

73 (2 by ULiège)

Number of downloads

58 (2 by ULiège)

More statistics

Scopus citations^®

0

Scopus citations^®
without self-citations

0

OpenCitations

0

Bibliography

Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Infammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015;110:1324-38.
Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017;376:1723-36.
Sandborn WJ, Panés J, D'Haens GR, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin Gastroenterol Hepatol 2019;17:1541-50.
Guillo L, Rabaud C, Choy EH, et al. Herpeszoster and vaccination strategies in infammatory bowel diseases: a practical guide. Clin Gastroenterol Hepatol 2020:S1542-3565.
Giménez Poderós T, Gallardo Borge S, Vazquez-Ferreiro P. Risk of venous thromboembolism associated with tofacitinib and baricitinib: a systematic review and indirect meta-analysis. Pharmacotherapy 2020;40:1248-64.
EuropeanMedicines Agency. Increased risk of blood clots in lungs and death with higher dose of Xeljanz (tofacitinib) for rheumatoid arthritis. Published online March 20, 2019. https://www.ema.europa.eu/en/news/increased-risk-blood-clots-lungs-death-higher-dose-xeljanz-tofacitinib-rheumatoid-arthritis.
Vermeire S, Su C, Lawendy N, et al. Outcomesof tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomized RIVETING trial. J Crohns Colitis 2020:S1542-3565.
Rubin DT, Travis S, Abraham BP, et al. Maintenance of effcacy following tofacitinib dose reduction in patients with ulcerative colitis in stable remission. J Crohns Colitis 2019;13:S425-6.
Sands BE, Armuzzi A, Marshall JK, et al. Effcacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcera-tive colitis: results from OCTAVE Open. Aliment Pharmacol Ther 2020;51:271-80.
Pariente B, Laharie D. Review article: Why, when and how to de-escalate therapy in infammatory bowel diseases. Aliment Pharmacol Ther 2014;40:338-53.
Siegel CA, Thompson KD, Walls D, et al. Perspectives from patients and gastroenterologists on de-escalating therapy for Crohn's disease. Clin Gastroenterol Hepatol 2021;19:403-5.
Sands BE, Moss AC, Armuzzi A, et al. Effcacy and safety of dose escalation to tofacitinib 10 Mg bid for patients with ulcerative colitis following loss of response on tofacitinib 5 Mg bid maintenance therapy: results from octave open. Gastroenterology 2018;154:S-385.
Louis E, Mary J-Y, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63-70.e5.
Fiorino G, Cortes PN, Ellul P, et al. Discontinuation of infiximab in patients with ulcerative colitis is associated with increased risk of relapse: a multinational retrospective cohort study. Clin Gastroenterol Hepatol 2016;14:1426-1432.e1.
Panés J, Bressler B, Colombel J F, et al. Effcacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption: results from the OCTAVE clinical trials. J Crohns Colitis 2018;12:S366-7.
Treton X, Bouhnik Y, Mary J-Y, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009;7:80-85.

Similar publications